NYSE:EVHEvolent Health Stock Price, Forecast & News

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EVH stock has increased by 82.2% and is now trading at $12.61.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolent Health.

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evolent Health.

Evolent Health Inc (NYSE:EVH) released its earnings results on Tuesday, August, 4th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.14. Evolent Health had a negative return on equity of 4.29% and a negative net margin of 53.56%.
View Evolent Health's earnings history.

Evolent Health updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $995M - 1.035 billion, compared to the consensus revenue estimate of $977.85 million.

11 equities research analysts have issued 1 year target prices for Evolent Health's shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Evolent Health's stock price to reach $13.56 in the next twelve months. This suggests a possible upside of 7.5% from the stock's current price.
View analysts' price targets for Evolent Health.

News headlines about EVH stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolent Health earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave media coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Evolent Health.

Some companies that are related to Evolent Health include Premier (PINC), Mantech International (MANT), R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Advanced Micro Devices (AMD), Chipotle Mexican Grill (CMG), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Ford Motor (F) and Cisco Systems (CSCO).

(EVH) raised $150 million in an initial public offering on Friday, June 5th 2015. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.41%), Bellevue Group AG (5.88%), Bank of New York Mellon Corp (2.22%), Silvercrest Asset Management Group LLC (2.10%), Formula Growth Ltd. (1.88%) and Glenmede Trust Co. NA (1.75%). Company insiders that own Evolent Health stock include Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley and Thomas Peterson III.
View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Glenmede Trust Co. NA, Goldman Sachs Group Inc., Gamco Investors INC. ET AL, Bank of America Corp DE, Formula Growth Ltd., Rock Point Advisors LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Evolent Health.

EVH stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Bellevue Group AG, Silvercrest Asset Management Group LLC, DC Investments Management LLC, Vanguard Group Inc., Profit Investment Management LLC, Cubist Systematic Strategies LLC, and Paradigm Capital Management Inc. NY. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley.
View insider buying and selling activity for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $12.61.

Evolent Health has a market capitalization of $1.08 billion and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.